Diagnostic Photonics (DxP) is a medtech company commercializing a handheld, high-resolution imaging system for cancer surgery. The Foresee™ (4C) Imaging System provides new, crucial information and insight on the extent of disease at the microscopic level. Surgeons can act on that information during surgery – no longer waiting days for final pathology – and avoid costly repeat procedures and poor clinical outcomes. In the company’s 50-patient, multi-center trial in breast cancer surgery, 62% of repeated surgeries could have been avoided. The Foresee™ system recently received CE-marking and initial FDA 510(k) clearance, and the company established new CPT coding (Cat III) to provide additional reimbursement for surgeons and healthcare facilities.
DxP is raising a $6M Series B round to conduct a 460-patient multi-center pivotal clinical trial for expanded US indication for use and insurance reimbursement / adoption. The company will also generate initial commercial sales at leading medical centers in North America and Europe.